Given the increasing rates of obesity and diabetes among African-Americans, Fowke and his colleagues sought a better understanding of the relationship between race, metabolic disorders and PSA levels used to detect early-stage prostate cancer.
The researchers examined participants in the Southern Community Cohort Study, a National Cancer Institute-funded initiative that monitors the health of 90,000 men and women between the ages of 40 and 79 throughout the southern United States. The researchers randomly selected 121 African-American men and 121 Caucasian men; each group had the same proportion of obese and overweight men, as determined by their BMI. Study participants had no prior diagnosis of cancer or diabetes.
From each participants blood sample, the researchers compared PSA levels with the amounts of HbA1c, C-peptide, leptin and adiponectin naturally occurring blood-borne molecules that have a biological role in metabolism, insulin activity, or the function of fat cells. Among African-Americans, PSA levels were 50 percent lower among men with higher levels of C-peptide, a biomarker that reliably indicates an increase in insulin. This association was especially prevalent among obese African-American men, Fowke says. PSA levels also declined somewhat among obese Caucasian men with high C-peptide levels, but this relationship was not as strong as it was in the African-American group.
The researchers saw a similar pattern in Caucasian men regarding the diabetes biomarker HbA1c, where PSA levels were 50 percent lower among men with higher levels of HbA1c. PSA levels were not associated with HbA1c in the African-American group, perhaps suggesting
'/>"/>
| Contact: Greg Lester greg.lester@aacr.org 267-646-0554 American Association for Cancer Research Source:Eurekalert |